AstraZeneca plc (ADR)  

(Public, NYSE:AZN)   Watch this stock  
Find more results for AZN
+0.37 (1.06%)
After Hours: 35.44 0.00 (0.00%)
Jan 19, 4:38PM EST  
NYSE real-time data - Disclaimer
Currency in USD
Range 35.33 - 35.58
52 week 26.51 - 35.92
Open 35.57
Vol / Avg. 2.53M/3.04M
Mkt cap 88.53B
P/E 25.34
Div/yield 0.45/3.95
EPS 1.40
Shares 1.27B
Beta 0.76
Inst. own 31%
Feb 2, 2018
Full Year 2017 AstraZeneca PLC Earnings Release - 2:00AM EST - Add to calendar
Jan 9, 2018
AstraZeneca PLC at SEB Nordic Seminar
Dec 14, 2017
AstraZeneca PLC Investor Science Event Late-Stage Pipeline Corporate Call - Webcast
Dec 7, 2017
AstraZeneca PLC at Berenberg European Conference
Dec 1, 2017
AstraZeneca PLC at Societe Generale Premium Review Conference
Nov 30, 2017
AstraZeneca PLC at Deutsche Bank dbAccess Pharmaceutical & Healthcare Corporate day
Nov 29, 2017
AstraZeneca PLC at Piper Jaffray Healthcare Conference
Nov 9, 2017
Q3 2017 AstraZeneca PLC Earnings Call
Nov 9, 2017
Q3 2017 AstraZeneca PLC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin 10.41% 14.81%
Operating margin 18.44% 21.31%
EBITD margin - 30.92%
Return on average assets 4.01% 5.56%
Return on average equity 20.10% 20.99%
Employees 59,700 -
CDP Score - A


1 Francis Crick Avenue Cambridge Biomedical Campus
United Kingdom - Map
+44-20-73045000 (Phone)
+44-20-76048151 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Officers and directors

Pascal Soriot Executive Director and Chief Executive Officer
Age: 57
Bio & Compensation  - Reuters
Marc Dunoyer Executive Director, Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Fiona Cicconi Executive Vice-President, Human Resources
Bio & Compensation  - Reuters
Sean Bohen M.D., Ph.D. Chief Medical Officer, Executive Vice President - Global Medicines Development
Bio & Compensation  - Reuters
Pam P. Cheng Executive Vice President - Operations and Information Technology
Age: 45
Bio & Compensation  - Reuters
Ruud Dobber Executive Vice President, North America
Bio & Compensation  - Reuters
Bahija Jallal Ph.D. Executive Vice President, MedImmune
Bio & Compensation  - Reuters
Mark Mallon Executive Vice President, Global Product and Portfolio Strategy, Global Medical Affairs & Corporate Affairs Executive Vice-President, International West
Bio & Compensation  - Reuters
Menelas Pangalos Executive Vice President - IMED Biotech Unit and Global Business Development
Bio & Compensation  - Reuters
Leon Wang Executive Vice President - Asia Pacific
Bio & Compensation  - Reuters